Hologic, Inc. (NASDAQ:HOLX) Shares Sold by V Square Quantitative Management LLC

V Square Quantitative Management LLC cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,966 shares of the medical equipment provider’s stock after selling 387 shares during the period. V Square Quantitative Management LLC’s holdings in Hologic were worth $502,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Creative Planning raised its holdings in Hologic by 16.6% during the third quarter. Creative Planning now owns 25,430 shares of the medical equipment provider’s stock worth $2,072,000 after purchasing an additional 3,617 shares in the last quarter. Swedbank AB raised its holdings in Hologic by 18.8% during the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after purchasing an additional 306,562 shares in the last quarter. Bleakley Financial Group LLC raised its holdings in Hologic by 23.9% during the third quarter. Bleakley Financial Group LLC now owns 6,368 shares of the medical equipment provider’s stock worth $519,000 after purchasing an additional 1,227 shares in the last quarter. Blue Trust Inc. raised its holdings in Hologic by 37.0% during the third quarter. Blue Trust Inc. now owns 7,118 shares of the medical equipment provider’s stock worth $528,000 after purchasing an additional 1,923 shares in the last quarter. Finally, OLD National Bancorp IN bought a new stake in Hologic during the third quarter worth approximately $204,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Trading Down 0.6 %

NASDAQ HOLX opened at $63.24 on Friday. Hologic, Inc. has a twelve month low of $62.94 and a twelve month high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.03 and a current ratio of 3.49. The stock has a market cap of $14.27 billion, a price-to-earnings ratio of 19.95, a PEG ratio of 2.14 and a beta of 0.97. The firm’s 50 day moving average price is $71.04 and its two-hundred day moving average price is $77.22.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current year.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.88% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Stephens reissued an “overweight” rating and set a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Needham & Company LLC cut Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a report on Monday, February 3rd. Morgan Stanley dropped their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Jefferies Financial Group started coverage on Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target on the stock. Ten investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $85.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.